Learn More
10751 Background: PLD has the advantage of delivering the active anthracycline directly to the tumour site, provide comparable efficacy to conventional doxorubicin with a more favourable toxicity(More)
18516 Background: Bone marrow supression is the main type of CT dose-limiting toxicity. Specific studies on HT impact factors are key to help establish appropriate protocols in routine patient care.(More)
  • 1